Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine
NCT05738213 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2025-10-16
Summary
The purpose of this research study is to investigate the relationships between sex hormone levels and experimental pain sensitivity and migraine severity will be examined.
Conditions
Interventions
- DEVICE
-
Thermal stimuli
The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
- DEVICE
-
Pressure stimuli
Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
- BEHAVIORAL
-
Pain ratings
Pain intensity and pain unpleasantness ratings will be assessed.
- BEHAVIORAL
-
Pressure pain thresholds (PPT)
Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
- BEHAVIORAL
-
Conditioned pain modulation (CPM) response
The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a "test" stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs.
- BEHAVIORAL
-
PedMIDAS (Pediatric Migraine Disability Assessment)
Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
- DIAGNOSTIC_TEST
-
Hormonal assessment
Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
- OTHER
-
Pubertal status
Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
Sponsors & Collaborators
-
International Headache Society
collaborator UNKNOWN -
Washington University School of Medicine
lead OTHER
Principal Investigators
-
Hadas Nahman-Averbuch, PhD · Washington University School of Medicine
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 11 Years
- Max Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-01-10
- Primary Completion
- 2025-07-14
- Completion
- 2028-01-01
Countries
- United States
Study Locations
More Related Trials
-
Mindfulness for Adolescents for CM and HFEM
NCT04968093 ·Status: COMPLETED ·Phase: NA
-
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675 ·Status: RECRUITING ·Phase: PHASE3
-
Gender Differences and Features of the Clinical Course of Primary Headaches
NCT05760625 ·Status: UNKNOWN
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394 ·Status: RECRUITING ·Phase: PHASE3
-
Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents
NCT01010711 ·Status: UNKNOWN ·Phase: NA
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
NCT06173661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Boston Migraine and Contraception Study
NCT01216358 ·Status: COMPLETED
-
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
NCT01329562 ·Status: COMPLETED ·Phase: PHASE4
-
Mindfulness-Based Intervention for Adolescents With Chronic Migraine
NCT06414109 ·Status: COMPLETED ·Phase: NA
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172 ·Status: RECRUITING ·Phase: PHASE3
-
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
NCT00259649 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Preventing Migraine Headaches in Children
NCT00237302 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine
NCT00567086 ·Status: COMPLETED ·Phase: PHASE2
-
Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2
NCT00374530 ·Status: COMPLETED ·Phase: NA
-
The Childhood and Adolescent Migraine Prevention Study
NCT01581281 ·Status: TERMINATED ·Phase: PHASE3
-
Mind and Body Approaches to Pain Reduction in Youth With Migraine
NCT03472092 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals
NCT00700128 ·Status: COMPLETED ·Phase: NA
-
Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine
NCT04604977 ·Status: COMPLETED ·Phase: NA
-
Adolescents With Migraine: What's Stress Got To Do With It?
NCT02259387 ·Status: COMPLETED
-
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine
NCT00131443 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment
NCT01814189 ·Status: COMPLETED ·Phase: PHASE3
-
Pediatric Chronic Headache Trial
NCT00389038 ·Status: UNKNOWN ·Phase: PHASE3
-
Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood
NCT01756209 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 ·Status: RECRUITING ·Phase: PHASE3